Distinct roles of different fragments of PDCD4 in regulating the metastatic behavior of B16 melanoma cells

Wang,Di; Guo,Shu; Han,Si-Yuan; Xu,Nan; Guo,Jia-Yan; Sun,Qing

doi:10.3892/ijo.2013.1841

Distinct roles of different fragments of PDCD4 in regulating the metastatic behavior of B16 melanoma cells

Authors:
- Di Wang
- Shu Guo
- Si-Yuan Han
- Nan Xu
- Jia-Yan Guo
- Qing Sun
View Affiliations

Affiliations: Department of Plastic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: February 27, 2013 https://doi.org/10.3892/ijo.2013.1841
Pages: 1725-1733

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is an aggressive cutaneous malignancy. In this study, we demonstrated that the levels of the programmed cell death 4 (PDCD4) protein and mRNA were lower in tumor tissues compared with normal tissues. In order to further investigate the effects of PDCD4 and its fragments in B16 melanoma cells, we established B16 clones with expression of different PDCD4 fragments. Intact PDCD4, PDCD4∆164‑469 and PDCD4∆327-440 expression, respectively, decreased proliferation and migration and increased apoptosis in B16 cells in vitro. We found that intact PDCD4, PDCD4∆164-469 or PDCD4∆327-440 can inhibit the activity of MMP-2 and the expression of CXCR4. However, PDCD4∆164-275 showed no effects on B16 cells. These results may prove helpful for the development of novel therapies for melanoma treatment.

View Figures

View References

1.	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Haass NK and Herlyn M: Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc. 10:153–163. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Haass NK, Smalley KS and Herlyn M: The role of altered cell– cell communication in melanoma progression. J Mol Histol. 35:309–318. 2004.
4.	Wang Q, Sun ZX, Allgayer H, et al: Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene. 29:128–138. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Shibahara K, Asano M, Ishida Y, et al: Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene. 166:297–301. 1995. View Article : Google Scholar : PubMed/NCBI
6.	Jansen AP, Camalier CE and Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 65:6034–6041. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Soejima H, Miyoshi O, Yoshinaga H, et al: Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet. 87:113–114. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Cmarik JL, Min H, Hegamyer G, et al: Differentially expressed protein PDCD4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 96:14037–14042. 1999. View Article : Google Scholar : PubMed/NCBI
9.	Chang JH, Cho YH, Sohn SY, et al: Crystal structure of the eIF4A-PDCD4 complex. Proc Natl Acad Sci USA. 106:3148–3153. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Suzuki C, Garces RG, Edmonds KA, et al: PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. Proc Natl Acad Sci USA. 105:3274–3279. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Yang HS, Cho MH, Zakowicz H, et al: A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol. 24:3894–3906. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Zakowicz H, Yang HS, Stark C, et al: Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA. 11:261–274. 2005. View Article : Google Scholar : PubMed/NCBI
13.	LaRonde-LeBlanc N, Santhanam AN, Baker AR, et al: Structural basis for inhibition of translation by the tumor suppressor Pdcd4. Mol Cell Biol. 27:147–156. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Chen Y, Knosel T, Kristiansen G, et al: Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 200:640–646. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Zhang H, Ozaki I, Mizuta T, et al: Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 25:6101–6112. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Afonja O, Juste D, Das S, et al: Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene. 23:8135–8145. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Mudduluru G, Medved F, Grobholz R, et al: Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 110:1697–1707. 2007. View Article : Google Scholar
18.	Motoyama K, Inoue H, Mimori K, et al: Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol. 36:1089–1095. 2010.PubMed/NCBI
19.	Jin H, Kim TH, Hwang SK, et al: Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther. 5:1041–1049. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Jansen AP, Camalier CE, Stark C, et al: Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 3:103–110. 2004.PubMed/NCBI
21.	Caporali S, Alvino E, Levati L, et al: Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem Pharmacol. 84:598–611. 2012. View Article : Google Scholar : PubMed/NCBI
22.	Yang CH, Yue J, Pfeffer SR, et al: MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem. 286:39172–39178. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Rothhammer T, Hahne JC, Florin A, et al: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 61:118–128. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Amara A, Gall SL, Schwartz O, et al: HIV coreceptor down-regulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. 186:139–146. 1997. View Article : Google Scholar : PubMed/NCBI
25.	Griffiths-Jones S, Grocock RJ, van Dongen S, et al: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Betel D, Wilson M, Gabow A, et al: The microRNA. org resource: targets and expression Nucleic Acids Res. 36:D149–D153. 2008.PubMed/NCBI
27.	Lankat-Buttgereit B and Goke R: The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol. 73:185–191. 2010. View Article : Google Scholar : PubMed/NCBI
29.	Yang HS, Jansen AP, Nair R, et al: A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation. Oncogene. 20:669–676. 2001.PubMed/NCBI
30.	Schmid T, Jansen AP, Baker AR, et al: Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 68:1254–1260. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Leupold JH, Yang HS, Colburn NH, et al: Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 26:4550–4562. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Böhm M, Sawicka K, Siebrasse JP, et al: The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene. 22:4905–4910. 2003.PubMed/NCBI
33.	Yang HS, Jansen AP, Komar AA, et al: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 23:26–37. 2003. View Article : Google Scholar
34.	Tawbi HA and Kirkwood JM: Management of metastatic melanoma. Semin Oncol. 34:532–545. 2007. View Article : Google Scholar : PubMed/NCBI
35.	Gibbs DF, Warner RL, Weiss SJ, et al: Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol. 20:1136–1144. 1999. View Article : Google Scholar : PubMed/NCBI
36.	Shah PK, Falk E, Badimon JJ, et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metal-loproteinases and implications for plaque rupture. Circulation. 92:1565–1569. 1995.
37.	Jackson C, Nguyen M, Arkell J, et al: Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis-targetting gelatinase A activation. Inflamm Res. 50:183–186. 2001. View Article : Google Scholar : PubMed/NCBI
38.	Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
39.	Kucia M, Jankowski K, Reca R, et al: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Schimanski CC, Schwald S, Simiantonaki N, et al: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 11:1743–1750. 2005. View Article : Google Scholar : PubMed/NCBI
41.	Harvey JR, Mellor P, Eldaly H, et al: Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res. 13:1562–1570. 2007. View Article : Google Scholar : PubMed/NCBI
42.	Zhou W, Jiang Z, Liu N, et al: Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol. 135:91–102. 2009. View Article : Google Scholar : PubMed/NCBI
43.	Turner RR, Ye X, Bilchik AJ, et al: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 244:113–120. 2006. View Article : Google Scholar : PubMed/NCBI
44.	Scala S, Giuliano P, Ascierto PA, et al: Human melanoma metastases express functional CXCR4. Clin Cancer Res. 12:2427–2433. 2006. View Article : Google Scholar : PubMed/NCBI